AstraZeneca vaccine and Guillain-Barré syndrome: There’s minimal cause for concern

by ·

The Therapeutic Goods Administration (TGA) yesterday revealed there have been six reports of Guillain-Barré syndrome in Australia following the AstraZeneca COVID vaccine.

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *

The information on this site is of a general nature only and is not intended to address the specific circumstances of any particular individual or entity. It is not intended or implied to be a substitute for professional advice. Read more.